Author: Dr. Yelena Janjigian (on-camera comments) – Courtesy of ESMO.org The Matterhorn study, a significant phase three global research effort, aims to determine the efficacy of a triplet regimen involving chemotherapy with flood alongside durvalumab in treating early-stage non-metastatic gastric and gastroesophageal adenocarcinoma. Presented at ESMO 2023, the study’s first interim analysis involved nearly 1000 … Continue reading MATTERHORN Trial Highlights the Transformative Potential of Durvalumab + FLOT in Gastric and GEJ Cancer Treatment